<DOC>
	<DOC>NCT02967692</DOC>
	<brief_summary>To evaluate the safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma</brief_summary>
	<brief_title>A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Inclusion criteria Part 1: Safety runin Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation Aspartate transaminase (AST) &lt; 2.5× ULN and Alanine transaminase (ALT) &lt; 2.5× ULN ECOG performance status ≤ 1 Part 2: Biomarker cohort Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation At least two cutaneous or subcutaneous or nodal lesions for tumor sample collection ECOG performance status ≤ 2 Part 3: Doubleblind, randomized, placebocontrolled part Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation ECOG performance status ≤ 2 Part 1: Safety runin Subjects with uveal or mucosal melanoma Any history of CNS metastases Prior systemic anticancer treatment for unresectable or metastatic melanoma Prior locoregional treatment for unresectable or metastatic melanoma in the last 6 month Prior neoadjuvant and/or adjuvant therapy for melanoma completed less than 6 months Radiation therapy within 4 weeks prior to start of study treatment Active, known, suspected or a documented history of autoimmune disease Parts 2 &amp; 3: Biomarker cohort &amp; doubleblind, randomized, placebocontrolled part Subjects with uveal or mucosal melanoma Clinically active cerebral melanoma metastasis Prior systemic anticancer treatment for unresectable or metastatic melanoma Prior locoregional treatment for unresectable or metastatic melanoma in the last 6 month Prior neoadjuvant and/or adjuvant therapy for melanoma completed less than 6 months Radiation therapy within 4 weeks prior to start of study treatment Active, known, suspected or a documented history of autoimmune disease Other protocoldefined Inclusion/Exclusion may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PDR001</keyword>
	<keyword>dabrafenib</keyword>
	<keyword>trametinib</keyword>
	<keyword>melanoma</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>PD 1 inhibitor</keyword>
	<keyword>anti PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>anti-PD-1</keyword>
	<keyword>combination treatment</keyword>
	<keyword>malignant skin cancer</keyword>
	<keyword>skin cancer</keyword>
	<keyword>BRAF V600</keyword>
	<keyword>unresectable BRAF V600 mutated melanoma</keyword>
	<keyword>metastatic BRAF V600 mutated melanoma</keyword>
</DOC>